Mirtazapine Viatris

Mirtazapine, the active ingredient in Mirtazapine Viatris, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and works through modulation of noradrenergic and serotonergic pathways. - Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Persistent depressive episode: helps alleviate lingering depressive signs when other treatments are insufficient. - Treatment‑resistant depression: may be added to enhance therapeutic response in patients not responding to first‑line agents.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness: often pronounced at treatment initiation. - Increased appetite and weight gain: may be significant over weeks. - Dry mouth: reduced salivary flow. - Constipation: slowed gastrointestinal motility. - Dizziness or light‑headedness: especially when standing quickly. - Peripheral edema: mild swelling of lower limbs.

Serious or Rare Side Effects: - Agranulocytosis: marked reduction in white blood cells. - Seizures: rare but possible, particularly in predisposed individuals. - Severe hypotension: abrupt drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Suicidal thoughts: emergence of new or worsening ideation. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate blood pressure and heart rate due to possible hypotension. - Metabolic monitoring: track weight, appetite changes, and lipid profile. - Psychiatric evaluation: monitor for emergence of suicidal thoughts or worsening depression. - Hepatic function: adjust use in patients with liver impairment. - Discontinuation strategy: taper gradually to avoid withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Anticholinergic agents: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): increased mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine): reduced therapeutic effect. - Alcohol: may exacerbate sedation and impair coordination.